Background Quinolones are potent broad-spectrum bactericidal agents increasingly employed also in resource-limited countries. Resistance to quinolones is an increasing problem, known to be strongly associated with quinolone exposure. We report on the emergence of quinolone resistance in a very remote community in the Amazon forest, where quinolones have never been used and quinolone resistance was absent in 2002. Methods The community exhibited a considerable level of geographical isolation, limited contact with the exterior and minimal antibiotic use (not including quinolones). In December 2009, fecal carriage of antibiotic resistant Escherichia coli was investigated in 120 of the 140 inhabitants, and in 48 animals reared in the community. All fluoroquinolone-resistant isolates were genotyped and characterized for the mechanisms of plasmid- and chromosomal-mediated quinolone resistance. Principal Findings Despite the characteristics of the community remained substantially unchanged during the period 2002–2009, carriage of quinolone-resistant E. coli was found to be common in 2009 both in humans (45% nalidixic acid, 14% ciprofloxacin) and animals (54% nalidixic acid, 23% ciprofloxacin). Ciprofloxacin-resistant isolates of human and animal origin showed multidrug resistance phenotypes, a high level of genetic heterogeneity, and a combination of GyrA (Ser83Leu and Asp87Asn) and ParC (Ser80Ile) substitutions commonly observed in fluoroquinolone-resistant clinical isolates of E. coli. Conclusions Remoteness and absence of antibiotic selective pressure did not protect the community from the remarkable emergence of quinolone resistance in E. coli. Introduction of the resistant strains from antibiotic-exposed settings is the most likely source, while persistence and dissemination in the absence of quinolone exposure is likely mostly related with poor sanitation. Interventions aimed at reducing the spreading of resistant isolates (by improving sanitation and water/food safety) are urgently needed to preserve the efficacy of quinolones in resource-limited countries, as control strategies based only on antibiotic restriction policies are unlikely to succeed in those settings.
References
[1]
Bolon MK (2009) The newer fluoroquinolones. Infect Dis Clin North Am 23: 1027–1051. doi: 10.1016/j.idc.2009.06.003
[2]
Thuo N, Ungphakorn W, Karisa J, Muchohi S, Muturi A, et al. (2011) Dosing regimens of oral ciprofloxacin for children with severe malnutrition: a population pharmacokinetic study with Monte Carlo simulation. J Antimicrob Chemother 66: 2336–2345. doi: 10.1093/jac/dkr314
[3]
Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I (2011) Ciprofloxacin safety in paediatrics: a systematic review. Arch Dis Child 96: 874–880. doi: 10.1136/adc.2010.208843
[4]
Okeke IN, Laxminarayan R, Bhutta ZA, Duse AG, Jenkins P, et al. (2005) Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect Dis 5: 481–493. doi: 10.1016/S1473-3099(05)70189-4
[5]
Lamikanra A, Crowe JL, Lijek RS, Odetoyin BW, Wain J, et al. (2011) Rapid evolution of fluoroquinolone-resistant Escherichia coli in Nigeria is temporally associated with fluoroquinolone use. BMC Infect Dis 11: 312. doi: 10.1186/1471-2334-11-312
[6]
Butler T (2011) Treatment of typhoid fever in the 21st century: promises and shortcomings. Clin Microbiol Infect 17: 959–963. doi: 10.1111/j.1469-0691.2011.03552.x
[7]
Traa BS, Walker CL, Munos M, Black RE (2010) Antibiotics for the treatment of dysentery in children. Int J Epidemiol 39: 70–74.
[8]
Souli M, Galani I, Giamarellou H (2008) Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 13(47):pii: 19045 http://www.eurosurveillance.org/ViewArti？cle.aspx?ArticleId=19045.
[9]
Chen TC, Lu PL, Lin CY, Lin WR, Chen YH (2011) Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis 15: 211–216.
[10]
Denton M (2007) Enterobacteriaceae. Int J Antimicrob Agents 29: 9–22. doi: 10.1016/j.ijantimicag.2006.08.024
Goettsch W, van Pelt W, Nagelkerke N, Hendrix MG, Buiting AG, et al. (2000) Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in the Netherlands. J Antimicrob Chemother 46: 223–228. doi: 10.1093/jac/46.2.223
[13]
Zervos MJ, Hershberger E, Nicolau DP, Ritchie DJ, Blackner LK, et al. (2003) Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991–2000. Clin Infect Dis 37: 1643–1648. doi: 10.1086/379709
[14]
Jensen US, Muller A, Brandt CT, Frimodt-M？ller N, Hammerum AM, et al. (2010) Effect of generics on price and consumption of ciprofloxacin in primary healthcare: the relationship to increasing resistance. J Antimicrob Chemother 65: 1286–1291. doi: 10.1093/jac/dkq093
[15]
Gottesman BS, Carmeli Y, Shitrit P, Chowers M (2009) Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clin Infect Dis 49: 869–875. doi: 10.1086/605530
[16]
Pallecchi L, Bartoloni A, Paradisi F, Rossolini GM (2008) Antibiotic resistance in the absence of antimicrobial use: mechanisms and implications. Expert Rev Anti Infect Ther 6: 725–732. doi: 10.1586/14787210.6.5.725
[17]
Thaller MC, Migliore L, Marquez C, Tapia W, Cede？o V, et al. (2010) Tracking acquired antibiotic resistance in commensal bacteria of Galápagos land iguanas: no man, no resistance. PLoS One 5: e8989. doi: 10.1371/journal.pone.0008989
[18]
Bartoloni A, Pallecchi L, Rodríguez H, Fernandez C, Mantella A, et al. (2009) Antibiotic resistance in a very remote Amazonas community. Int J Antimicrob Agents 33: 125–129. doi: 10.1016/j.ijantimicag.2008.07.029
[19]
Bartoloni A, Benedetti M, Pallecchi L, Larsson M, Mantella A, et al. (2006) Evaluation of a rapid screening method for detection of antimicrobial resistance in the commensal microbiota of the gut. Trans R Soc Trop Med Hyg 100: 119–125. doi: 10.1016/j.trstmh.2005.06.027
[20]
Bartoloni A, Pallecchi L, Benedetti M, Fernandez C, Vallejos Y, et al. (2006) Multidrug-resistant commensal Escherichia coli in children, Peru and Bolivia. Emerg Infect Dis 12: 907–913. doi: 10.3201/eid1206.051258
[21]
Clinical and Laboratory Standards Institute (2009) Performance standards for antimicrobial disk susceptibility tests. Supplement M02-A10. CLSI, Wayne, PA, USA.
[22]
Clinical and Laboratory Standards Institute (2011) Performance standards for antimicrobial susceptibility testing. Supplement M100-S21. CLSI, Wayne, PA, USA.
[23]
Bartoloni A, Pallecchi L, Riccobono E, Mantella A, Magnelli D, et al. (2012) Relentless increase of resistance to fluoroquinolones and expanded-spectrum cephalosporins in Escherichia coli: 20 years of surveillance in resource-limited settings from Latin America. Clin Microbiol Infect doi: 10.1111/j.1469-0691.2012.03807.x. doi: 10.1111/j.1469-0691.2012.03807.x
[24]
Riccobono E, Pallecchi L, Mantella A, Bartalesi F, Zeballos IC, et al. (2012) Carriage of antibiotic-resistant Escherichia coli among healthy children and home-raised chickens: a household study in a resource-limited setting. Microb Drug Resist 18: 83–87. doi: 10.1089/mdr.2011.0003
[25]
Bansal S, Tandon V (2011) Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in Escherichia coli clinical isolates. Int J Antimicrob Agents 37: 253–255. doi: 10.1016/j.ijantimicag.2010.11.022
[26]
Bartoloni A, Pallecchi L, Fiorelli C, Di Maggio T, Fernandez C, et al. (2008) Increasing resistance in commensal Escherichia coli, Bolivia and Peru. Emerg Infect Dis 14: 338–340. doi: 10.3201/eid1402.070138
[27]
Davidson RJ, Davis I, Willey BM, Rizg K, Bolotin S, et al. (2008) Antimalarial therapy selection for quinolone resistance among Escherichia coli in the absence of quinolone exposure, in tropical South America. PLoS One 3: e2727. doi: 10.1371/journal.pone.0002727
[28]
Marcusson LL, Frimodt-M？ller N, Hughes D (2009) Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog 5: e1000541. doi: 10.1371/journal.ppat.1000541
[29]
Michon A, Allou N, Chau F, Podglajen I, Fantin B, et al. (2011) Plasmidic qnrA3 enhances Escherichia coli fitness in absence of antibiotic exposure. PLoS One 6: e24552. doi: 10.1371/journal.pone.0024552
